On May 23rd, KAIST (President Kwang-Hyung Lee) announced that its Digital Bio-Health AI Research Center (Director: Professor JongChul Ye of KAIST Kim Jaechul Graduate School of AI) has been selected for the Ministry of Science and ICT's 'AI Top-Tier Young Researcher Support Program (AI Star Fellowship Project).' With a total investment of ₩11.5 billion from May 2025 to December 2030, the center will embark on the full-scale development of AI technology and a platform capable of independently inferring and determining the kinds of diseases, and discovering new drugs.
< Photo. On May 20th, a kick-off meeting for the AI Star Fellowship Project was held at KAIST Kim Jaechul Graduate School of AI’s Yangjae Research Center with the KAIST research team and participating organizations of Samsung Medical Center, NAVER Cloud, and HITS. [From left to right in the front row] Professor Jaegul Joo (KAIST), Professor Yoonjae Choi (KAIST), Professor Woo Youn Kim (KAIST/HITS), Professor JongChul Ye (KAIST), Professor Sungsoo Ahn (KAIST), Dr. Haanju Yoo (NAVER Cloud), Yoonho Lee (KAIST), HyeYoon Moon (Samsung Medical Center), Dr. Su Min Kim (Samsung Medical Center) >
This project aims to foster an innovative AI research ecosystem centered on young researchers and develop an inferential AI agent that can utilize and automatically expand specialized knowledge systems in the bio and medical fields.
Professor JongChul Ye of the Kim Jaechul Graduate School of AI will serve as the lead researcher, with young researchers from KAIST including Professors Yoonjae Choi, Kimin Lee, Sungsoo Ahn, and Chanyoung Park, along with mid-career researchers like Professors Jaegul Joo and Woo Youn Kim, jointly undertaking the project. They will collaborate with various laboratories within KAIST to conduct comprehensive research covering the entire cycle from the theoretical foundations of AI inference to its practical application.
Specifically, the main goals include:
- Building high-performance inference models that integrate diverse medical knowledge systems to enhance the precision and reliability of diagnosis and treatment.
- Developing a convergence inference platform that efficiently combines symbol-based inference with neural network models.
- Securing AI technology for new drug development and biomarker discovery based on 'cell ontology.'
Furthermore, through close collaboration with industry and medical institutions such as Samsung Medical Center, NAVER Cloud, and HITS Co., Ltd., the project aims to achieve:
- Clinical diagnostic AI utilizing medical knowledge systems.
- AI-based molecular target exploration for new drug development.
- Commercialization of an extendible AI inference platform.
Professor JongChul Ye, Director of KAIST's Digital Bio-Health AI Research Center, stated, "At a time when competition in AI inference model development is intensifying, it is a great honor for KAIST to lead the development of AI technology specialized in the bio and medical fields with world-class young researchers." He added, "We will do our best to ensure that the participating young researchers reach a world-leading level in terms of research achievements after the completion of this seven-year project starting in 2025."
The AI Star Fellowship is a newly established program where post-doctoral researchers and faculty members within seven years of appointment participate as project leaders (PLs) to independently lead research. Multiple laboratories within a university and demand-side companies form a consortium to operate the program.
Through this initiative, KAIST plans to nurture bio-medical convergence AI talent and simultaneously promote the commercialization of core technologies in collaboration with Samsung Medical Center, NAVER Cloud, and HITS.
* Focusing on nurturing talent and dedicating to R&D to become a G3 AI powerhouse (Top 3 AI Nations). * Leading the realization of an "AI-driven Basic Society for All" and developing technologies that leverage AI to overcome the crisis in Korea's manufacturing sector. * 50 years ago, South Korea emerged as a scientific and technological powerhouse from the ashes, with KAIST at its core, contributing to the development of scientific and technological talent, innovative technology, national
2025-06-24< Photo 1. Professor Jaesik Choi, KAIST Kim Jaechul Graduate School of AI > Recently, text-based image generation models can automatically create high-resolution, high-quality images solely from natural language descriptions. However, when a typical example like the Stable Diffusion model is given the text "creative," its ability to generate truly creative images remains limited. KAIST researchers have developed a technology that can enhance the creativity of text-based image generati
2025-06-20KAIST announced on the 16th of June that it has launched the ‘InnoCORE (Innovation-Core) Research Group,’ which will lead advanced strategic research in AI convergence (AI+S&T), in cooperation with the Ministry of Science and ICT (Minister Yoo Sang-im, hereinafter referred to as MSIT) and DGIST, GIST, and UNIST*. Through this, the group plans to actively recruit up to 200 world-class postdoctoral researchers. DGIST (Daegu Gyeongbuk Institute of Science & Technology), GIST
2025-06-19< Photo 1. (From left) Professor Hyunwoo Kim and students Donghun Kim and Gyeongseon Choi in the Integrated M.S./Ph.D. program of the Department of Chemistry > Thalidomide, a drug once used to alleviate morning sickness in pregnant women, exhibits distinct properties due to its optical isomers* in the body: one isomer has a sedative effect, while the other causes severe side effects like birth defects. As this example illustrates, precise organic synthesis techniques, which selectivel
2025-06-16· A team led by Professor Won Do Heo from the Department of Biological Sciences, KAIST, has developed a pioneering technology that selectively acetylates specific RNA molecules in living cells and tissues. · The platform uses RNA-targeting CRISPR tools in combination with RNA-modifying enzymes to chemically modify only the intended RNA. · The method opens new possibilities for gene therapy by enabling precise control of disease-related RNA without affecting the rest of the
2025-06-10